Sign in
SGMT Stock Price, Chart, Stats & News
Sagimet Biosciences Inc.
Save
214.55M
Market cap
–
Current P/E
–
Forward P/E
SGMT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -43.82% |
ROE | -40.85% |
D/E | 0.00x |
Interest coverage ratio | – |
SGMT valuation
P/E | – |
P/S | – |
P/B | 1.42x |
P/CF | -3.46x |
P/FCF | -3.43x |
P/OCF | -3.46x |
PEG | -0.28x |
EV multiple | -3.37x |
About
Sagimet Biosciences Inc. is a biopharmaceutical company with drug candidates in clinical trials, specializing in developing therapies that target fatty acid synthase (FASN) inhibition. These treatments are engineered to combat medical conditions stemming from impaired lipid metabolism pathways. Its primary investigational compound, Denifanstat, is a FASN inhibitor currently being evaluated for nonalcoholic steatohepatitis (NASH) and acne.
Similar securities
Based on sector and market capitalization
Report issue